Optimal sample sizes for phase II clinical trials and pilot studies

Statistics in Medicine

Volumn 31, Issue 11-12, 2012, Pages 1031-1042

  Stallard, Nigel ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Adaptive programmes of clinical development; Bayesian decision theory; Clinical trial design

Indexed keywords

ARTICLE; BAYES THEOREM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; PROCESS OPTIMIZATION; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STUDY DESIGN;

BAYES THEOREM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; PILOT PROJECTS; SAMPLE SIZE;

EID: 84861183854     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4357     Document Type: Article

References (21)

1. Whitehead J. Designing phase II studies in the context of a programme of clinical research. Biometrics 1985; 41:373-383.
2. Whitehead J. Sample sizes for phase II and phase III clinical trials: an integrated approach. Statistics in Medicine 1986; 5:459-464.
3. Stallard N. Decision-theoretic designs for phase II clinical trials allowing for competing studies. Biometrics 2003; 59:402-409.
4. Julious SA, Swank DJ. Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics 2005; 4:37-46.
5. Yao T-J, Begg CB, Livingston PO. Optimal sample size for a series of pilot trials of new agents. Biometrics 1996; 52:992-1001.
6. Yao T-J, Venkatraman ES. Optimal two-hand design for a series of pilot trials of new agents. Biometrics 1998; 54:1183-1189.
7. Wang Y-G, Leung DHY. An optimal design for screening trials. Biometrics 1998; 54:245-252.
8. Ding M, Rosner GL, Müller P. Bayesian optimal design for phase II screening trials. Biometrics 2008; 64:886-894.
9. Berger JO. Statistical decision theory and Bayesian Analysis, 2nd ed. Springer-Verlag: New York, 1985.
10. Smith JQ. Decision Analysis: A Bayesian Approach. Chapman and Hall: London, 1988.
11. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2009.
12. Genz A, Bretz F, Miwa T, Mi X, Leisch F, Scheipl F, Hothorn T. mvtnorm: Multivariate normal and t distributions version 09-92, 2010.
13. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. Journal of Evaluation in Clinical Practice 2004; 10:307-312.
14. Liu Q, Anderson K, Pledger GW. Benefit-risk evaluation of multi-hand adaptive designs. Sequential Analysis 2004; 23:317-331.
15. Hardwick JP, Stout QF. Exact computational analyses for adaptive designs. In Adaptive Designs, Flournoy N, Rosenberger WF (eds). IMS: Hayward, CA, 1995; 223-237.
16. Stallard N. Sample size determination for phase II clinical trials based on Bayesian decision theory. Biometrics 1998; 54:279-294.
17. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006; 48:623-634.
18. Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biometrical Journal 2006; 48:635-643.
19. Stallard N, Todd S. Seamless phase II/III designs. Statistical Methods in Medical Research. DOI: 10.1177/0962280210379035 [Available online ahead of print].
20. Schoenfeld D. Statistical considerations for pilot studies. International Journal of Radiation Oncology, Biology and Physics 1980; 6:371-374.
21. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics 2005; 4:287-291.